A study published in JAMA Neurology found that F-18 FDG-PET imaging can track brain metabolism changes over time in patients with prodromal dementia with Lewy bodies and probable DLB. Those two patient cohorts had greater metabolic decline in specific brain regions over 3.8 years, when compared with a group of patients without cognitive impairment.

The 2024 US Prostate Cancer Conference released 34 consensus recommendations on clinical decision-making in advanced prostate cancer related to novel therapies where high-quality evidence is lacking. The panel of experts made recommendations, published in the journal Cancer, on the use of PSMA PET/CT and other treatment modalities.

ImaginAb co-founder Anna Wu discusses developments in immune system imaging and targeted radiopharmaceuticals. Her team's work focuses on imaging of immune cells, with a focus on CD8 T cells, that can monitor immune responses before and after cancer immunotherapy.

Eckert & Ziegler will supply actinium-225 to GlyTherix under a new agreement to advance the development of alpha radiotherapeutics for cancer treatment. This collaboration focuses on using a radionuclide-antibody combination to target Glypican-1, a protein associated with aggressive cancers.

Nonprofit hospitals are expected to see better financial performance this year, driven by easing labor costs and increased patient volumes, according to Fitch Ratings. Some hospitals, particularly smaller ones and those in areas with stagnant population growth, may continue to struggle.

A study in the Journal of Clinical Investigation found that more than 15 million people in the US were diagnosed with autoimmune diseases from 2011 to 2022, with women nearly twice as likely to be affected as men. The research, using electronic health records from six health care systems, highlights rheumatoid arthritis as the most prevalent condition.

Korea's radiopharmaceutical industry is transitioning from diagnostic agents to therapeutic radiopharmaceuticals, with companies like SK biopharmaceuticals, DuChemBio, CellBion, and FutureChem seeking to establish themselves in this competitive market. Innovations include SK biopharmaceuticals' Actinium-225, an alpha-emitting radionuclide that could be a potential successor to Lutetium-177.

President Joe Biden's administration is expected to propose legislation limiting nicotine levels in cigarettes, excluding e-cigarettes and nicotine replacement products, in a last-minute effort to combat tobacco use. The proposal may aim to reduce nicotine levels by up to 95% to make cigarettes less addictive, potentially saving millions of lives.

The Peterson Health Technology Institute has formed a task force to evaluate AI technologies for health care delivery, focusing on ambient scribes and revenue cycle management tools. The task force, which has been in operation for six months, includes executives from a dozen health systems, such as UC San Diego Health and Intermountain Health. A report on AI-powered ambient scribes and revenue cycle management tools is expected this quarter.